Targeting autolysin ATL of Streptococcus suis : structural insights and inhibition by lanreotide acetate
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag326 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Huiming Han und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medicine, Beihua University, Jilin, China. Hauptthemen laut MEDLINE: Streptococcus suis, Somatostatin, N-Acetylmuramoyl-L-alanine Amidase, Anti-Bacterial Agents. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Beihua University Graduate Innovation and Entrepreneurship Training Program, Science and Technology projects, Jilin Province Department of Education.
Abstract (Originalsprache)
Background
Streptococcus suis serotype 2 (SS2) is an important zoonotic pathogen that causes severe infections in pigs and humans. Bacterial autolysins play essential roles in cell-wall remodelling and virulence; however, the structural and functional characteristics of the SS2 autolysin ATL remain poorly understood. With the increasing emergence of antimicrobial resistance, anti-virulence strategies that attenuate bacterial pathogenicity without directly inhibiting growth have attracted increasing attention.
Methods
ATL domain organization was analysed bioinformatically. The catalytic domain was expressed, purified and crystallized, and its structure was determined at 1.8 Å resolution. An atl deletion mutant was generated, and ATL function was evaluated by autolysis, biofilm formation, adhesion and mouse infection assays. Lanreotide acetate was assessed for its effects on bacterial growth, ATL inhibition and anti-virulence activity in vitro and in vivo.
Results
ATL contains cell-wall-binding repeats and a C-terminal Zn2+-dependent amidase domain with a His13–Glu27–His81 catalytic site. Deletion of atl did not affect bacterial growth but reduced autolysis, biofilm formation, adhesion and virulence in mice. Lanreotide acetate had a minimum inhibitory concentration (MIC) of 512 mg/L and showed no growth inhibition at sub-MIC concentrations. However, it inhibited ATL activity and reduced autolysis, biofilm formation, adhesion, barrier penetration and bacterial burden, while alleviating splenic pathology.
Conclusions
ATL is a key SS2 virulence-associated autolysin. Lanreotide acetate attenuates SS2 pathogenicity by inhibiting ATL activity without suppressing bacterial growth, supporting ATL as a potential anti-virulence target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Basic Medicine, Beihua University, Jilin, China.
- Center for Infection and Immunity, Beihua University, Jilin, China.
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Department of Science and Education, Affiliated Hospital of Beihua University, Jilin, China.
Förderung
- Beihua University Graduate Innovation and Entrepreneurship Training Program
- Science and Technology projects
- Jilin Province Department of Education
- Jilin Province Health and Family Planning Commission
Zitieren
APA
Han, H., Zhang, D., Zhang, X., Li, Y., Zheng, S., Zhou, D., Hou, Q., Li, G., & Li, S. (2026). Targeting autolysin ATL of Streptococcus suis : structural insights and inhibition by lanreotide acetate. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag326
Vancouver
Han H, Zhang D, Zhang X, Li Y, Zheng S, Zhou D, et al. Targeting autolysin ATL of Streptococcus suis : structural insights and inhibition by lanreotide acetate. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag326
BibTeX
@article{Han2026,
author = {Han, Huiming and Zhang, Duo and Zhang, Xindan and Li, Yifei and Zheng, Shuai and Zhou, Di and Hou, Qinlong and Li, Gen and Li, Shuang},
title = {Targeting autolysin ATL of Streptococcus suis : structural insights and inhibition by lanreotide acetate},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag326}
}
EUVIMED